[작성자:] Claire
-
3billion is attending ESHG Conference 2026 in Gothenburg
If you’re attending the European Society of Human Genetics (ESHG) Conference 2026 in Gothenburg this June, we’d like to meet you. 3billion will be on site from June 13–16 at Booth #620, and we’d welcome the chance to talk through the diagnostic challenges you’re working on. Stop by and you’ll be able to see how…
-
What Is a Lymphatic Malformation? Causes, Inheritance, and Diagnosis
📍Key Takeaways What is a lymphatic malformation? A lymphatic malformation is a congenital vascular malformation made up of abnormally dilated lymphatic channels and cysts. It was historically called a lymphangioma, and the large-cyst form in the neck was called a cystic hygroma. The three terms essentially describe the same disease group. It is categorized by…
-
림프관 기형이란? 원인과 유전 여부, 유전자 검사의 필요성
📍Key Takeaways 림프관 기형이 무엇인가요? 림프관 기형(lymphatic malformation)은 비정상적으로 확장된 림프관과 낭으로 이루어진 선천성 혈관 기형입니다. 과거에는 림프관종(lymphangioma)으로, 특히 목에 생기는 거대낭형은 낭성 림프관종(cystic hygroma)으로 불렸습니다. 세 용어는 사실상 같은 질환군을 가리킵니다. 낭의 크기에 따라 거대낭형, 미세낭형, 혼합형으로 구분됩니다. 국제혈관기형학회(ISSVA) 분류에서 림프관 기형은 증식하는 혈관 종양이 아니라 저유량 혈관 기형으로 분류됩니다. 종양이 아니라 태아 발달…
-
Genomic and Genetic Technologies in Clinical Practice Conference 2026
3billion is attending the Genomic and Genetic Technologies in Clinical Practice conference, taking place on June 3–4, 2026, at Narxoz Business School in Almaty, Kazakhstan. The conference brings together clinical geneticists and genomic specialists to explore the expanding role of genetic technologies in routine clinical care. Our team is looking forward to contributing to that…
-
What Does Heterozygous Mean in Your Genetic Report?
Being heterozygous means you inherited two different versions (alleles) of a gene — one from each biological parent. For example, an A blood-type allele from one parent and a B allele from the other. This is a basic building block for understanding how traits are inherited. Whether it affects your health depends on the specific…
-
3billion Launches 3B-NEO, a Genomic Newborn Screening Service Covering 704 Clinically Actionable Genetic Conditions
SEOUL, South Korea, June 1, 2026 — 3billion, a global AI-powered genomic diagnostics company, today announced the launch of 3B-NEO, a premium genomic newborn screening (gNBS) service designed to identify genetic risks before symptoms appear and support earlier medical intervention. 3B-NEO was developed in response to growing demand from international healthcare providers and global partners…
-
쓰리빌리언, 유전체 기반 신생아 선별검사 ‘3B-NEO’ 해외 출시…글로벌 gNBS 시장 진출
AI 기반 희귀질환 진단 기업 쓰리빌리언(대표 금창원)은 유전체 기반 신생아 선별검사 서비스 ‘3B-NEO’를 공식 출시한다고 1일 밝혔다. 3B-NEO는 생후 90일 이내 신생아를 대상으로 유전질환 위험을 조기에 확인하는 유전체 기반 신생아 선별검사(Genomic Newborn Screening, gNBS) 서비스다. 쓰리빌리언은 미국·유럽 등을 중심으로 gNBS 시장이 연구 단계를 넘어 본격 상업화되고, 기존 글로벌 고객들의 신생아 선별검사 수요가 지속 증가함에 따라…
-
NIPT for Prenatal, 3B-NEO for Postnatal: Comprehensive Screening from Day One
*Please note that as of the date of this post, 3B-NEO is not yet available in South Korea. During pregnancy, NIPT is the gold standard for protecting your baby before birth. But what happens once your newborn finally arrives? In the first few days of life, hospitals perform routine physical checks and basic newborn blood…
-
41 Patients Found New Answers Through Reanalysis of Genetic Testing: May 2026
Is a single genetic test result the end of the diagnostic journey?At 3billion, we believe diagnosis is an ongoing process. That’s why we focus not only on the test itself, but on what comes after:Reanalysis. For all cases previously reported as Inconclusive or Negative,3billion performs automated reanalysis through a continuous system.Each month, dozens of reports…
-
2026년 5월, 41명의 환자가 재분석을 통해 의미있는 결과를 받았어요!
2026년 5월에도 Inconclusive/Negative 리포트를 새롭게 받은 환자가 41명 있습니다. 어떻게 새로운 진단을 받았을까요? 유전체 검사를 한 번 했다고 진단이 끝났다고 생각하시나요?3billion은 ‘검사’ 그 자체보다 더 중요한 과정을 이야기합니다.바로 재분석입니다. 쓰리빌리언은 모든 불확정(Inconclusive) 또는 음성(Negative) 결과에 대해 자동화된 시스템으로 재분석을 진행하고 있습니다.이 과정은 거의 매일 진행되고 있죠. 단순히 다시 돌리는 것이 아니라 새로운 변이와 질환 데이터베이스와,…